RxDoctor Payments Data

Lynn Lang, MD

Family Medicine · Yuba City, CANPI 1942399050

Payments from drug & device makers

$13,856in general payments, 2019–2025

Across 738 payments — averaging $18.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • AbbVie$2K
  • AstraZeneca$1K
  • Amarin Pharma, Inc.$745
  • GSK$595
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$478
  • plus $6K from 51 others

What the payments were for

  • Food & beverage$13,72999%
  • Education$1271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,856 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$400,860
Medicare patients
147
Services billed
16,911

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide70$87,520
VraylarCariprazine Hcl32$44,836
Breztri AerosphereBudesonide/Glycopyr/Formoterol43$36,993
MounjaroTirzepatide30$29,690
ProliaDenosumab17$29,087
Repatha SureclickEvolocumab18$11,254
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$10,814
Raloxifene Hcl34$1,500
Rosuvastatin Calcium67$1,327
Telmisartan53$1,204
Montelukast Sodium59$717
Duloxetine Hcl19$634
Ezetimibe24$574
Pregabalin13$472
Gabapentin24$354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$345$87,52070 claims
AbbVieVraylar$2,446$44,83632 claims
AstraZenecaBreztri Aerosphere$1,109$36,99343 claims
Lilly USA, LLCMounjaro$378$29,69030 claims
AmgenProlia$2,572$29,08717 claims
GSKTrelegy Ellipta$595$10,81413 claims
Almatica Pharma LLCSertraline Hcl$80$9916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Yuba City

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →